Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49
   PubMed Web of Science ®Google Scholar
• Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2006;25:293
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-15
   PubMed Web of Science ®Google Scholar
• Chapple C, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
   PubMed Web of Science ®Google Scholar
• Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001;57:1044-50
   Google Scholar
• Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7:455-63
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher C, Lerr L, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6:580-90
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006;97:96-100
   PubMed Web of Science ®Google Scholar
• Roberts R, Bavendam T, Glasser DB, et al. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int J Clin Pract 2006;60:752-58
   PubMed Web of Science ®Google Scholar
• Brubaker L, Chapple C, Coyne KS, et al. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006;68:3-8
   PubMed Web of Science ®Google Scholar
• Matza LS, Brewster-Jordan J, Zyczynski T, et al. An updated review of quality-of-life questionnaires for urinary incontinence and overactive bladder: which ones to use and why. Current Bladder Dysfunction Reports 2006;1:71-80
   Google Scholar
• Freeman R, Hill S, Millard R, et al. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 2003;102:605-11
   PubMed Web of Science ®Google Scholar
• Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol 2004;22:251-6
   PubMed Web of Science ®Google Scholar
• Rackley R, Weiss JP, Rovner ES, et al. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006;67:731-6
   PubMed Web of Science ®Google Scholar
• Homma Y, Paick JS, Lee JG, et al. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 2003;92:741-7
   PubMed Web of Science ®Google Scholar
• van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414-21
   PubMed Web of Science ®Google Scholar
• Sussman DO, Kraus SR, Carlsson M, et al. Onset of efficacy of tolterodine extended release in patients with overactive bladder. Curr Med Res Opin 2007;23:777-81
   PubMed Web of Science ®Google Scholar
• Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002;24:616-28
   PubMed Web of Science ®Google Scholar
• Rudy D, Cline K, Harris R, et al. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int 2006;97:540-6
   PubMed Web of Science ®Google Scholar
• Matza LS, Thompson CL, Krasnow J, et al. Test–retest reliability of four questionnaires for patients with overactive bladder: the Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ). Neurourol Urodyn 2005;24:215-25
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Kopp Z, et al. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006;49:1079-86
   PubMed Web of Science ®Google Scholar
• Coyne KS, Tubaro A, Brubaker L, et al. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 2006;68:9-16
   PubMed Web of Science ®Google Scholar
• Translations of the PPBC. Available at: http://www.oabq.com/ppbctranslate.html [Last accessed 11 April 2007]
   Google Scholar
• McKown S, Coyne KS, Reilly K, et al. Linguistic validation of the patient perception of bladder condition questionnaire (PPBC) in 10 languages. Value Health 2006; 9A392(#PUK25)
   Web of Science ®Google Scholar
• Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563-74
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Thompson CL, et al. Determining the importance of change in the overactive bladder questionnaire. J Urol 2006;176:627-32
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Reese PR, Pleil AM, et al. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002;8:608-15
   PubMed Web of Science ®Google Scholar
• Donaldson MM, Thompson JR, Matthews RJ, et al. The natural history of overactive bladder and stress urinary incontinence in older women in the community: a 3-year prospective cohort study. Neurourol Urodyn 2006;25:709-16
   PubMed Web of Science ®Google Scholar
• Khullar V, Hill S, Laval K-U, et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 2004;64:269-75
   PubMed Web of Science ®Google Scholar
• Landis JR, Kaplan S, Swift S, et al. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol 2004;171:752-6
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296:2319-28
   PubMed Web of Science ®Google Scholar
• van Leeuwen JHS, Castro R, Busse M, et al. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006;50:440-53
   PubMed Web of Science ®Google Scholar